TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02653742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
Study: NCT02806804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose test vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose commercially available trivalent influenza vaccine
Study: NCT02653742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
Study: NCT03806920

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention D
Study: NCT02455271

Intervention type: DRUG
Intervention: Eszopiclone
Description: The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
Study: NCT02806804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of Quadrivalent Influenza Virus Vaccine
Study: NCT01359319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER) Tablets
Description: Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER) Tables
Description: PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
Study: NCT03034330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-Tier Stroke Family Empowerment
Description: The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volunteer Support Psychoeducation
Description: The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
Study: NCT04649463

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Open ABPM results
Description: ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Open ABPM results
Description: ABPM results were used in the decision making for adjustments in antihypertensive medication at follow up visit.
Study: NCT00746434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast cream
Description: Roflumilast cream 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream
Study: NCT01905449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrasound visual feedback
Description: Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrasound visual feedback
Description: Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
Study: NCT03558490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZEMY software
Description: The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigator's choice of anti-cancer treatment (except immunotherapy)
Description: All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
Study: NCT01359319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER) Tablets
Description: Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER) Tablets
Description: Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER) Tablets
Description: Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
Study: NCT01199874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: live attenuated oral rotavirus vaccine; lyophilized; 1 ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: live attenuated oral rotavirus vaccine; lyophilized; 1 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: live attenuated oral rotavirus vaccine; lyophilized; 1 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: live attenuated oral rotavirus vaccine; lyophilized; 1 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: live attenuated oral rotavirus vaccine; lyophilized; 1 ml
Study: NCT04357834

Intervention type: OTHER
Intervention: Equipment with smartwatch throughout hospital stay on the general ward
Description: Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.
Study: NCT04061668

Intervention type: OTHER
Group type: OTHER
Intervention: single needle path PECS I and II block group
Description: The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: double needle path PECS I and II block group
Description: The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
Study: NCT02408016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Description: Given IV
Study: NCT01799005

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol (410 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (no flavanols)
Study: NCT01590693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
Study: NCT03975686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscual realigning exercise
Description: neuromuscular realigning exercise
Study: NCT00720343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline
Description: Oral Choline 20 grams before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin Capsule
Study: NCT01754493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
Study: NCT02008773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir HCI 500 mg tablets
Description: Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules 6/day oral for 16 weeks
Study: NCT00769509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy expenditure in preterm fed with preterm formula
Description: Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment of energy expenditure
Description: assessment of energy expenditure in preterm infant during fed with human milk with fortifier
Study: NCT02408016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02324582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous MK-3475/ Intravesical BCG
Description: 6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
Study: NCT01139229

Intervention type: OTHER
Group type: OTHER
Intervention: hybrid everted esophagogastric anastomosis

Intervention type: OTHER
Group type: OTHER
Intervention: the conventional hand-sewn anastomosis
Study: NCT03824340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline before ICSI
Description: Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
Study: NCT02694107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT03511495

Intervention type: DIAGNOSTIC_TEST
Intervention: Galilei Corneal Topographer
Description: A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
Study: NCT01139229

Intervention type: OTHER
Group type: OTHER
Intervention: a stapled anastomosis
Study: NCT03622424

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis200
Description: Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis200 and Placebo
Description: Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
Study: NCT04433754

Intervention type: OTHER
Intervention: biochemical analysis
Description: cRP, d-dimer levels and lymphocyte counts will be compared

Intervention type: OTHER
Intervention: biochemical analysis
Description: cRP, d-dimer levels and lymphocyte counts will be compared
Study: NCT01427699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2-18C3 therapeutic antibody
Description: 1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
Study: NCT00417170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg tablets taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg capsule taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aliskiren
Description: Placebo Aliskiren taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Amlodipine
Description: Placebo Amlodipine taken orally once daily
Study: NCT03078686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tSVF by lipoaspiration
Description: Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tSVF by lipoaspiration
Description: Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tSVF by lipoaspiration
Description: Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP Concentration
Description: Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP Concentration
Description: Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP Concentration
Description: Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emulsification tSVF
Description: Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emulsification tSVF
Description: Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cSVF isolation and concentration
Description: Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cSVF isolation and concentration
Description: Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cSVF in Normal Saline IV
Description: cSVF + NS for IV Placement
Study: NCT01875328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Post stroke follow up in home using telemedicine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic
Description: Post stroke clinic group follow up
Study: NCT00442962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: 600-mg tablet taken orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
Study: NCT02612285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
Study: NCT03278626

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolimumab+Carboplatin/paclitaxel+Radiation
Description: In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
Study: NCT01085071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
Study: NCT02144194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine-Docetaxel
Description: Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine-Docetaxel
Description: Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
Study: NCT00962104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken by mouth, once daily for 10 weeks.